Source - Alliance News

Syncona Ltd - investor in healthcare companies - Notes investee company Achilles Therapeutics PLC posts widened loss amid rising research & development costs. Pretax loss in the quarter ended March 31 widens to $17.3 million from $13.8 million a year ago. Research & development costs surge to $13.0 million from $8.9 million, mainly due to increased activity in ongoing clinical trials. Cash and equivalents on March 31 fall to $236.9 million from $266.3 million as of December 31. ‘The company anticipates that its cash and cash equivalents are sufficient to fund its planned operations into the second half of 2024,’ Achilles says.

Achilles is developing personalised T cell therapies for the treatment of solid tumours, specifically targeting neo-antigens.

Current stock price: 170.20 pence

12-month change: down 22%

Copyright 2022 Alliance News Limited. All Rights Reserved.

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts

Syncona Limited (SYNC)

+0.20p (+0.16%)
delayed 17:53PM